Severe gastroenteritis as presentation of a neuroendocrine tumor of pancreas
DOI:
https://doi.org/10.18203/2349-2902.isj20232644Keywords:
PanNEt, Severe gastroenteritis, VIP, PancreaticoduodenectomyAbstract
Pancreatic neuroendocrine tumors (PanNETs) are a very rare entity, corresponding to 1-2% of all pancreatic neoplasms, although incidence and prevalence are rising. According to hormonal production, they can be functional or nonfunctional, leading to a subset of symptoms. A 45-year-old man, came to our emergency department complaining of vomiting and profuse non-bloody diarrhea for a week, with asthenia and no improvement with medication. He presented with diminished muscular strength and severe electrolytic changes with electrocardiographic repercussion. Patient was admitted to our intensive care unit (ICU) for hypovolemic and distributive shock due to a severe gastroenteritis. Further research studies were carried out which have shown a nodular structure of 5x4cm in the pancreas tail on computed tomography scan. A biopsy was made, and a histopathological exam revealed a pancreatic well differentiated neuroendocrine tumor. Hormonal analysis showed an elevation on vasoactive intestinal polypeptide (VIP). On 68Ga-DOTA-NOC PET/CT, there were 2 nodular lesions with anomalous overexpression of somatostatin receptors, one in the pancreatic tail near splenic hilum and another in the pancreatic head. Patient underwent a total pancreaticoduodenectomy with en bloc splenectomy. Postoperative period was uneventful. Mostly, this kind of pancreatic neuroendocrine tumors are indolent, but till 39% can have an aggressive course, so they have variable prognosis.
References
Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15(2):409-27.
Klimstra DS. Nonductal neoplasms of the pancreas. Mod Pathol. 2007;20(1):S94.
Angelousi A, Koffas A, Grozinsky-Glasberg S, Gertner J, Kassi E, Alexandraki K, et al. Diagnostic and Management Challenges in Vasoactive Intestinal Peptide Secreting Tumors: A Series of 15 Patients. Pancreas. 2019;48(7):934-42.
Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021;17(4):207-24.
Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011.
Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006;30(5):643-53.
Schizas D, Mastoraki A, Bagias G, Patras R, Moris D, Lazaridis II, et al. Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review. J BUON. 2019;24(2):415-23.
Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T. Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male. Hematol Oncol Stem Cell Ther. 2014;7(3):109-15.
Una Cidon E. Vasoactive intestinal peptide secreting tumor: An overview. World J Gastrointest Oncol. 2022;14(4):808-19.
Azizian A, König A, Hartmann A, Schuppert F, Seif Amir Hosseini A, Kitz J, et al. Surgical treatment of metastatic VIPoma: a case report. Therap Adv Gastroenterol. 2021;14:17562848211051132.
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Fact sheet: Neuroendocrine and Adrenal Tumors, Version 1. 2023. Available at: https://www.nccn.org/ guidelines/guidelines-detail?category=1&id= 1448. Accessed on 23 March 2023.
Sakurai M, Wakabayashi T, Kondo Y, Ikeda E, Watanabe K, Takei A, et al. A case of vasoactive intestinal peptide-secreting tumor (VIPoma) arising from MEN1 inactivation which recurred 15 years after the initial resection. Endocr J. 2023;70(6):573-9.
